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In vitro studies on the potential use of 5-aminolaevulinic acid-mediated
photodynamic therapy for gynaecological tumours
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Summary Results are reported on the sensitivity of various gynaecological tumour cell lines to 5-
aminolaevulinic acid-induced protoporphyrin IX-sensitised photodynamic therapy (ALA-PDT) in vitro. All
cell lines tested accumulated ALA-induced protoporphyrin IX (PpIX) and demonstrated good sensitivity to
ALA-PDT. Localisation of PpIX in the mitochondria was demonstrated by fluorescence microscopy.
Subcellular damage following ALA-PDT was observed using transmission electron microscopy. This damage
was localised initially to the mitochondria, with damage to membranes and the nucleus and complete loss of
intracytoplasmic organisation being observed subsequently. There was no apparent difference in ALA-PDT
response between a multidrug-resistant ovarian carcinoma cell line and its parent line. These results indicate
that ALA-PDT has potential for application to therapy of gynaecological malignancies.
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Gynaecological malignancies represent a challenge to the
medical community. The incidence of preinvasive squamous
carcinoma has risen dramatically over the past decade and it
has been predicted that mortality caused by cervical
carcinoma will increase 20% by the year 2000 unless
significant improvements in screening techniques are
achieved (Beral and Booth, 1986). While the response to
surgery, radiotherapy and chemotherapy is relatively good
for early stages of the disease, there is a high mortality rate in
advanced, multifocal or recurrent cancers (Corti et al., 1987;
Cannistra, 1993). The vast majority ofpatients with advanced
ovarian cancer die of the disease (Ozols and Young, 1991),
with overall survival rates not improving over the last 20
years. Further, the current clinical approaches to treatment
are not suitable for all patients, especially for elderly women.
Photodynamic therapy (PDT) is an alternative approach
to cancer treatment that has, in the last 20 years, yielded very
encouraging results (Dougherty and Marcus, 1992). This
technique involves the administration of a non-toxic dose of
a photosensitising compound that is selectively retained by
malignant tissues. Light in the visible range of the
electromagnetic spectrum is then used to activate the drug
in situ. This activated drug initiates a series of chemical
reactions that leads to the selective destruction of the
malignant tissues. This promising new treatment modality
has already been used clinically for the experimental detection
and treatment of various types of tumour, including bladder,
oesophagus, skin, lung and gynaecological malignancies
(Dougherty and Marcus, 1992). The combination of surgery
with PDT offers a number of advantages when compared
with chemotherapy. No intrinsic resistance to PDT, general
toxicity or cumulative toxicity has been observed to date. The
short half-life of the cytotoxic species and the mechanism of
action of PDT ensure that the damage is localised primarily
to the malignant tissues, sparing adjacent normal tissues.
There is no reported risk of mutagenesis. PDT generally
requires fewer treatments than radiation therapy, is cost-
effective and is relatively non-invasive (Levy, 1994). It can be
performed following debulking of large tumours during
excisional surgery.
The clinically most widely used photochemotherapeutic
reagent to date has been photofrin (PF, porfimer sodiumR,
photofrin II), along with several similar preparations such as
dihaematoporphyrin ether (DHE), haematoporphyrin deriva-
tive (HpD) and polyhaematoporphyrin (PHP). Phase III
studies in the USA with PF have focused on obstructive
tumours of lung and oesophagus (Levy, 1994). The use of
PDT in gynaecological lesions has provided encouraging
results in preliminary studies (Corti et al., 1987; DeLaney et
al., 1993 and references therein). For example, DeLaney
reports phase I clinical trials using combined debulking
surgery and DHE-PDT for disseminated intraperitoneal
tumours. In Japan, PF has been used on cervical carcinoma
in situ with a 94% complete response rate (Kato et al., 1993).
To date, PF has been approved for photochemotherapeutic
treatment of the following malignancies: cervical (Japan),
superficial bladder (Canada), oesophageal (Canada and The
Netherlands), stomach (Japan) and lung (Japan and The
Netherlands).
PF-PDT shows a useful degree of specificity for many
malignant tissues, but the slow clearance rate of PF from
normal tissues leads to prolonged skin photosensitivity
(several weeks to several months). It is necessary therefore
to wait at least several weeks between treatments to permit
drug clearance and maintain the original level of tissue
specificity. Current protocols for PF are limited to a total of
three treatments. The search for other photosensitisers with
more suitable properties is ongoing (Dougherty and Marcus,
1992).
An effective alternative to PF-PDT involves the use of the
endogenous photosensitiser protoporphyrin IX (PpIX)
(Kennedy and Pottier, 1992), which is induced to accumulate
by administration of its metabolic precursor 5-aminolaevu-
linic acid (ALA). Administration of ALA bypasses the
feedback control system in the haem biosynthetic pathway,
resulting in cellular/tissue accumulation of photosensitising
amounts of PpIX. Although PpIX biosynthesis is an active
pathway in all nucleated cells, preferential formation/
accumulation of PpIX has been demonstrated in malignant
tissues (Batlle, 1993; Kennedy and Pottier, 1994). ALA-PDT
has been used previously on a variety of normal and
malignant cell types in vitro (Malik and Lugaci, 1987;
linuma et al., 1994), with a significant response to PDT by
the malignant cells and lower response by the normal cells.
Therapeutic application of ALA-PDT to skin and gastro-
intestinal malignancies has given very encouraging prelimin-
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ary results (Kennedy and Pottier, 1994; Cairnduff et al., 1994;
Gossner et al., 1995; Lang et al., 1995; Lui et al., 1995;
Mlkvy et al., 1995; Regula et al., 1995).
Previously there have been few reports of gynaecological
applications of ALA-PDT. It has been used for endometrial
ablation and to prevent embryonic implantation in laboratory
animals (Yang et al., 1993, 1994, 1995; Wyss et al., 1994).
ALA-PDT has been used clinically in the treatment ofovarian
carcinoma metastatic in the vaginal vault with satisfactory
debulking of the tumour (JC Kennedy, unpublished observa-
tions). In this study, we have determined the in vitro sensitivity
of cell lines originating from cervical, ovarian and mammary
tumours in order to provide information on the potential
suitability of ALA-PDT for gynaecological tumours.
Materials and methods
Cell lines
HeLa cells (cervical epithelioid carcinoma), SiHa cells
(cervical squamous carcinoma) and MDA-MB-231 cells
(mammary adenocarcinoma) were obtained from the ATCC
Collection Facilities (Bethesda, MD, USA). A2780-9S
(ovarian carcinoma) and 2780AD cells (a doxorubicin-
resistant variant of A2780-9S) were obtained from Dr RF
Ozols (NCI Bethesda, MD, USA) through Dr SPC Cole
(Queen's University, Kingston, Canada). All cell lines were
maintained in 25 ml tissue culture flasks (Corning, NY, USA)
at 37°C and 5% carbon dioxide, in RPMI-1640 medium
(Gibco, Burlington, Ontario, Canada), supplemented with
10% fetal bovine serum (FBS) (Gibco) and 1% glutamine.
Cells were subcultured when confluent using 0.5% Trypsin-
10% ethylenediaminetetraacetic acid (EDTA) in phosphate-
buffered saline (PBS), pH 7.4, to release the cells. All
chemicals and solvents were reagent grade.
ALA incubation
For this and all subsequently described protocols, cells were
plated close to confluency (2 x 106 cells ml-1) in RPMI (with
10% FBS) in 3 cm diameter wells of a six-well Falcon tissue
culture plate (Becton Dickinson, Lincoln Park, NJ, USA),
and left to attach overnight. Cells were then incubated in the
dark in RPMI (no FBS or phenol red) with freshly prepared
5-aminolaevulinic acid hydrochloride (ALA) (Fluka Chemical
Corp., Rankonkoma, NY, USA) at concentrations between 0
and 10 mM for 0 to 28 h at 37°C. For all subsequent
handling, great care was taken to avoid exposing the cells to
unwanted light.
Measurement of PpIX accumulation
Following ALA incubation, cells were removed from the cell
culture wells by vigorous pipetting, pelleted by centrifugation
(2000 r.p.m. for 6 min), and resuspended in 350 ,l of RPMI
in 5 ml polystyrene flow cytometry tubes (Falcon). Accumu-
lation of protoporphyrin IX (PpIX) fluorescence induced by
ALA was assessed by an EPICS Elite flow cytometer (Coulter
Electronics, Burlington, Ontario, Canada) as previously
described (Campbell et al., 1996). This method allowed the
individual examination of the fluorescence emitted by several
thousands of cells (n>5000). The 488 nm line of an argon
ion laser was used as an excitation source (at a power of
100 mW), and a 630/20 nm bandpass (BP) (20 nm full width
halfmaximum) filter was placed on the emission side in order
to isolate the PpIX fluorescence signal. DNA-Check beads
(Coulter Electronics) were used to standardise the system and
minimise variability between experiments. The autofluores-
cence of the control sample was subtracted from the mean
fluorescence intensity of each sample and these values were
expressed in arbitrary fluorescence units. The data were not
corrected for differences in cell volume as all of the cell lines
had similar volumes as assessed by the measurement of the
forward scatter on the flow cytometer (Campbell et al., 1996).
Spectroscopy
Cell samples were incubated with ALA and pelleted as
described above. Fluorescence emission and excitation
spectra were obtained from the pellets, using a fluorimetry
system described elsewhere (Dickson et al., 1995). To obtain
emission spectra, excitation light from a Xe lamp filtered
through a 410/10 nm BP filter was directed through one arm
of a bifurcated fibre bundle onto the sample. The fluorescence
was collected through the other arm of the bifurcated fibre
bundle and sent to a linear diode array spectrophotofluo-
rometer which recorded the entire emission spectrum through
a 535 nm long pass (LP) filter. To obtain excitation spectra, a
filter was placed on the excitation side which passed 400-
650 nm; emission through a 710/10 nm BP filter was
quantified while scanning the excitation wavelength, using a
stepping monochromator, every 5 nm between 350 and
670 nm. The excitation spectra were corrected for excitation
intensity.
Cell photosensitisation
Cells, incubated with ALA as previously described, were
light-treated with a tungsten lamp equipped with a heat filter
and a 600-700 nm BP filter. The photosensitising light was
focused perpendicularly on the cell culture well, which was
placed on a rotating holder to ensure uniformity of
irradiation (irradiance 70+10 mW cm-2), determined using
an apertured calorimetric detector (Sciencetech 380101,
Boulder, CO, USA). After a predetermined time of light
exposure, cells were collected and labelled with fluorescent
dyes in order to assess cell viability by flow cytometry as
described elsewhere (Campbell et al., 1996). In brief, cells
were labelled using the Live-Dead Eukolite Viability/
Cytotoxicity Kit (L-3224, Molecular Probes Inc., Eugene
OR, USA). This kit uses two fluorescent dyes to assess vital
functions. One dye, calcein AM, is converted by intracellular
esterases to calcein, which fluoresces at 535 nm and is
retained by viable cells. The other dye, ethidium homo-
dimer-1, penetrates damaged membranes of dead or dying
cells, binds to nucleic acids and fluoresces at 640 nm. RPMI
(100 ,l) containing ethidium homodimer-1 (4 ,UM) and calcein
AM (2 LM) were added to each cell sample. Cells were then
incubated for 30 min in the dark at 37°C before the flow
cytometric measurements. Specific fluorescence was detected
by the use of a 525/30 nm BP filter (for calcein) and a
595 nm LP filter (for ethidium). This technique permits one
to gate electronically on whole single cells (excluding debris
and clumps), using forward scatter vs side scatter informa-
tion.
Fluorescence microscopy
Fluorescence microscopic studies were performed using a
system that combines a cooled charge-coupled device (CCD)
camera imaging system with either a Leitz Aristoplan
epifluorescence microscope or a Meridian confocal micro-
scope. Such a system permits switching from a cytological to
a fluorescent image of the same cells. The epifluorescence
microscope was equipped with a 100 W mercury lamp filtered
with an 13 filter cassette (excitation 450-490 nm, dichroic
510 nm, barrier filter 520 nm LP). The light source for the
confocal microscope was the 488 nm line of an argon ion
laser, and the microscope was equipped with a filter wheel
containing eight selections for filtering the emission light. All
images were captured using a cooled CCD camera (Meridian
Instruments, Okemos, MI, USA), and were digitised using a
MCID-M4 microcomputer system (Imaging Research, St.
Catherine's, Ontario, Canada). Subconfluent cells were
incubated on glass coverslips in the presence of ALA or
media under the conditions described above. Coverslips were
then mounted on a slide and observed with a 100 x oil
immersion objective lens through a 620/40 nm BP filter to
observe PpIX fluorescence. For the mitochondrial co-In vitro ALA-PDT for gynaecological tumours
FM Rossi et a! 9
883
localisation studies, the cells on the coverslips were further
incubated for 10 min in 10 jug ml-' rhodamine 123 in RPMI
(without phenol red), rinsed in RPMI without phenol red,
then observed as previously described through a 525/30 nm
BP filter. The no ALA and no rhodamine controls exhibited
no cross-fluorescence under the experimental conditions used.
Electron microscopy
Cells were incubated with ALA, irradiated (when required)
and collected as previously described. Cells were centrifuged
(1 min, 12 000 r.p.m.), fixed in 2% paraformaldehyde-0.5%
glutaraldehyde in 0.2 M cacodylate buffer, post-fixed in 1%
osmium in 0.1 M cacodylate buffer for 1 h, dehydrated in
ethanol and embedded in epon 812 (epoxy resin). Thin
sections (70 nm) were stained with uranyl acetate and lead
citrate and then observed in a Hitachi H500 transmission
electron microscope (TEM).
Results
ALA-induced accumulation of PpIX
Figure 1 shows that the emission and excitation spectra
observed from the A2780-9S cell pellets correspond to those
of PpIX. No fluorescence emission spectrum characteristic of
other endogenous porphyrins was observed. Similar results
were obtained for all of the cell lines studied.
After dark incubation with ALA, all the cell lines studied
showed some degree ofporphyrin accumulation, with a broad
histogram of fluorescence intensities. Figure 2 shows that the
accumulation of PpIX, as judged by the PpIX fluorescence
intensity, increased with the time of dark incubation, and
tended towards aplateau after 5 h for mostcell lines. However,
in no case was an actual plateau reached for incubation times
up to 28 h. OnlytheA2780-9S cells appear to accumulate PpIX
at linearly increasing concentrations for up to 28 h.
Figure 3 shows that at concentrations of ALA lower than
2.5 mM, PpIX accumulation appeared to be dose dependent,
but all cell lines showed an accumulation plateau for
concentration of ALA greater than 5 mM. At higher ALA
doses (10 mM) there was, for the A2780-9S and SiHa cells, a
small decrease in accumulation, possibly owing to the acidity
of the ALA solution exceeding the buffer capability of the
medium. Based on the above results, a concentration of ALA
corresponding to the plateau region of the PpIX accumula-
tion vs ALA concentration curves (5 mM) was used for all
further experiments.
ALA-induced photosensitisation
After incubation with ALA, the cells became very sensitive to








multilogarithmic killing was very rapid and directly
dependent on the amount of energy delivered. Under these
experimental conditions, there were no significant differences
in the amount of cell killing among different cell lines. Light
treatment alone did not kill the cells. No decrease in ALA-
PDT killing efficacy was observed for the doxorubicin-
resistant cells (2780AD) relative to the non-resistant equiva-
lent. Cell kill was dependent upon the duration of dark
incubation with ALA before irradiation, that is, on the
amount of PpIX that had accumulated. Incubation of cells in
ALA for 20 h resulted in more photosensitisation than
incubation for 5 h.
PpIX localisation
Subcellular localisation of PpIX was studied by fluorescence
microscopy. Figure Sa shows the very distinctive intracellular
PpIX fluorescence distribution with a punctate pattern in the
perinuclear region. The extranuclear distribution of the PpIX
fluorescence was confirmed by comparing the images of the
same cells taken in bright field and epifluorescence modes.
The punctate pattern of the fluorescence indicated a
subcellular organelle distribution. Figure Sb shows that,
after co-incubating the cells with ALA and rhodamine 123,
the same intracellular fluorescence pattern could be observed
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Figure 2 Protoporphyrin IX accumulation as a function of time
of incubation of cells in the dark with 5mM ALA. (0) HeLa
cells, (0) A2780-9S cells, (A) 2780AD cells, (D) SiHa cells, (v)
MDA-MB-231 cells. Each data point represents the average of at


















Figure 1 Characteristic protoporphyrin IX excitation (a) and
emission (b) spectra obtained from pelleted A2780-9S cells
incubated with 5mM ALA in the dark for 5h.
Figure 3 Protoporphyrin IX accumulation obtained after 12h of
dark incubation ofcells, as a function ofALA concentration. (0)
HeLa cells, (0) A2780-9S cells, (A) 2780AD cells, (O) SiHa cells,
(v) MDA-MB-231 cells. Each data point represents the average
of at least three determinations, with a standard deviation less
than 15%.In vitro ALA-PDT for gynaecological tumours
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mitochondria [Rhodamine is a known stain for mitochondria
(Shapiro, 1994)].
The location of subcellular phototoxic damage was studied
by transmission electron microscopy. TEM pictures taken
after cell incubation with ALA and different doses of light
showed diffuse mitochondrial alterations as an early
phenomenon (Figure 6), with mitochondria swollen and
showing enlarged intercristae spaces. At higher light doses
(Figure 7), vacuolisation and vesiculation of the cytoplasm,
condensation of the nuclear chromatin, swelling of the
nuclear membrane and rounding of the cellular shape were
observed. At even later stages the integrity of the cytoplasmic
membrane and the cytoplasmic structure was lost and the
nuclei appeared pycnotic.
Discussion
Results obtained in this in vitro study clearly show that cell
lines derived from gynaecological tumours can accumulate
ALA-induced PpIX, exhibiting a significant degree of PpIX
fluorescence. There is a significant correlation between ALA
incubation time, that is, the amount of PpIX accumulation,
and efficacy of ALA-PDT, as judged by the survival curves.
A minimum of three logs of cell kill can be obtained by
ALA-PDT at doses > 15 J cm-2 of red light for larger
amounts of accumulated PpIX. Although in vitro work on
cell lines cannot be extrapolated directly to in vivo systems,
these results, along with other preliminary results obtained in
our laboratory on surgical specimens, indicate that ALA-
induced PpIX may be useful in the detection and treatment
of gynaecological tumours. ALA-PDT has been used to treat
an ovarian carcinoma metastatic in the vaginal vault, which
showed a good clinical response with adequate tissue
specificity (JC Kennedy, unpublished results).
For detection purposes, HpD fluorescence has been a
useful tool, showing good correlation with histological
findings in delineating the limits of cervical lesions (Gray et
al., 1967; Kyriazis et al., 1973). PpIX fluorescence has been
used in the same manner, for example in the bladder
(Svanberg et al., 1993; Kriegmair et al., 1994), and should
find clinical usefulness in detection of metastatic gynaecolo-
gical tumours also.
Drug resistance is a serious problem for conventional
chemotherapy and has been reported also for PDT using
photofrin in tissue culture. Cell lines resistant to PF-PDT
have also shown cross-resistance to other therapeutic
methods. Chinese hamster ovary fibroblast multidrug-
resistant (CHO-MDR) cells have shown cross-resistance to
PF-PDT (Singh et al., 1991; Mitchell et al., 1988). In this case
u.u 0 5 10 15 20 25 30
Dose of light (J cm-2)
Figure 4 Survival of cells incubated with 5mM ALA for 5 h (A)
and 20h (*) as a function of light dose. Each data point
represents the average of at least three determinations, with a
standard deviation less than 15%. There was no significant cell
death following light treatment alone.
Figure 5 Characteristic (a) PpIX and (b) rhodamine fluorescence
distributions in SiHa cells incubated 20h with 5mM ALA, and
then for 10min with rhodamine 123. Photographs were taken
through a 620nm BP filter (for PpIX) and 530nm BP filter (for
rhodamine).In vitro ALA-PDT for gynaecological tumours
FM Rossi et al
rigure -i L/su- ceiis incuoatea tor Lun wiltfi JmM ALA. (a) Figure 6 MDA-MB-231 cells incubated for 20h with 5mM ALA. Control cell (no light); (b) cell exposed to 6.3J cm-2 light dose;
(a) Control cell (no light); (b) cell exposed to 4.2J cm light (c) mitochondria ofcontrol cell; (d) mitochondria of exposed cell.
dose; (c) mitochondria of control cell; (d) mitochondria of Note in the light-exposed cells the marked swelling of the
exposed cell. Note swelling of mitochondria, loss of microvilli mitochondria with enlargement of intercristae space, vacuolisa-
and condensation of nuclear chromatin after light exposure. tion of cytoplasm, rupture of cytoplasmic membrane and loss of
cytoplasmic structure, swelling of the nuclear membrane and
nuclear pycnosis. These phenomena were seen in all cell types
multidrug resistance conferred some degree of PF-PDT
resistance but the converse was not true. In contrast, a
MDR human breast cancer line was not PF-PDT resistant
(Mitchell et al., 1988). PF-PDT-resistant radiation-induced
fibrosarcoma (RIF) cells have shown cross-resistance to
cisplatin, but do not exhibit multidrug resistance (Moore-
head et al., 1994). Mouse tumour cells resistant to PF-PDT
also did not exhibit a multidrug resistance phenotype nor did
they have altered porphyrin uptake properties (Luna and
Gomer, 1991). Explanations for these various observations
include altered subcellular localisation of photosensitiser,
photodamage repair mechanisms or plasma and mitochon-
drial membrane potentials, with different mechanisms existing
in general for PF-PDT- and multidrug-induced resistance.
Possible mechanisms for drug resistance in general include,
for example, altered drug transport (implicated in multidrug
resistance), increased metallothionein or glutathione levels,
altered DNA adduct formation and/or repair and altered
membrane potentials. For ALA-PDT, our data indicate that
there is no significant difference in response between the
doxorubicin- resistant (MDR) ovarian cell line 2780AD and its
doxorubicin-sensitive parental cell line. Thus, at least in these
cells, multidrug resistance does not appear to confer any
resistance to ALA-PDT. We have also demonstrated that
cisplatin-resistant small-cell lung cancer cells do not show
resistance to ALA-PDT (Campbell et al., 1995).
The mechanisms for accumulation and the sites of
phototoxic damage are different for ALA-induced PpIX
(this study and linuma et al., 1994) and PF (Schneckenburger
et al., 1988; Berns et al., 1982; Moan et al., 1989; Salet and
Moreno, 1990; Kessel, 1986). PF passes from the extracellular
environment into the plasma membrane, and from there is
believed to migrate to various intracellular sites including the
nuclear and mitochondrial membranes. Various transport
processes must be involved and sites of action can be
different depending on the delivery method. On the other
examined.
hand, since the PpIX is synthesised largely in the
mitochondria (Batlle, 1993), no PpIX transport is required
before accumulation in the location sensitive to damage.
Mitochondrial alterations suggest that this organelle is in fact
a primary site of ALA-PDT damage. TEM results obtained
in this study are similar to those previously reported on cells
incubated with haematoporphyrin (Milanesi et al., 1989;
Malik et al., 1992), ALA (Malik and Lugaci, 1987) and PF
(Evensen et al., 1988; Leunig et al., 1994; Ning and Pan,
1985). Observations common to all cell lines studied included
swollen mitochondria, loss of microvilli and vacuolisation
and vesiculation of the cytoplasm. Also observed are the
enlargement of the nuclear membrane, probably owing to
influx of water in the inner space as the two membranes are
still connected at the level of the nuclear pores, and rupture
of the plasma membrane leading to complete loss of
intracytoplasmic organisation. Nuclear alterations included
condensation of the chromatin and a pycnotic appearance of
the nuclei. From the flow cytometric data obtained at various
light doses (not shown), it can be seen that at low doses of
light, early damage is manifested as increased permeability of
the plasma membrane (decrease in the calcein fluorescence)
without a concomitant increase in ethidium fluorescence; at
higher light doses nuclear membrane permeability increases
(increase in ethidium fluorescence). This suggests that nuclear
alterations are the consequence of an indirect process, which
may imply a Ca2+ imbalance resulting in activation of
endonucleases.
While several questions on the detailed mechanism of
ALA-PDT mode of action still remain to be solved, our
results indicate that ALA induces the accumulation of
fluorescing and photosensitising concentrations of PpIX in
a panel of malignant gynaecological cell lines. Studies are
-
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planned to evaluate the clinical potential of this phenomenon.
To date, good clinical responses have been seen in
preliminary patient studies of ALA-PDT in breast second-
aries in the chest wall (Kennedy and Pottier, 1992) and in
cervical and ovarian carcinoma involving the vaginal vault
(JC Kennedy, unpublished observations).
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